Phase 1, multi-center, open-label, dose-escalation study to:~Evaluate the safety profile and MTD of RP-6306 alone and in combination with RP-3500 when administered orally to establish the recommended Phase 2 dose and schedule~Characterize the PK and pharmacodynamics of RP-6306 alone and in combination with RP-3500~Assess preliminary anti-tumor activity associated with RP-6306 alone and in combination with RP-3500
The primary purpose of this study is to assess the safety and tolerability of RP-6306 alone and in combination with RP-3500 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.